Biomedical Technology Assessment

The OBA Biomedical Technology Assessment Program is responsible for monitoring and assessing the scientific, ethical, and social implications of biotechnologies and, as warranted, monitors the development and integration of those technologies into scientific and clinical practice.





On March 22, 2016, the NIH Office of Science Policy published a Federal Register notice detailing the revised procedures for the review of human gene transfer trials subject to the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules (NIH Guidelines).  These changes are effective April 27, 2016.  The changes to the human gene transfer protocol review process are being made after NIH, in consultation with the Institute of Medicine, determined that the NIH Recombinant DNA Advisory Committee’s (RAC) review of individual human gene transfer trials should be limited to cases in which an oversight body (such as an Institutional Biosafety Committee or an Institutional Review Board) determines that a protocol would significantly benefit from RAC review.

A summary of the changes can be found in the following RAC Revisions Factsheet.




Frequently Asked Questions